%D8%AF%D8%A7%D8%A8%D9%8A%D8%BA%D8%A7%D8%AA%D8%B1%D8%A7%D9%86Category:DabigatranDabigatranDabigatranDabigatr%C3%A1nDabigatraaniDabigatran%D7%93%D7%91%D7%99%D7%92%D7%98%D7%A8%D7%90%D7%9FDabigatran%E3%83%80%E3%83%93%E3%82%AC%E3%83%88%E3%83%A9%E3%83%B3%D0%94%D0%B0%D0%B1%D0%B8%D0%B3%D0%B0%D1%82%D1%80%D0%B0%D0%BDDabigatran%D0%94%D0%B0%D0%B1%D0%B8%D0%B3%D0%B0%D1%82%D1%80%D0%B0%D0%BD%D0%B0_%D1%8D%D1%82%D0%B5%D0%BA%D1%81%D0%B8%D0%BB%D0%B0%D1%82DabigatranDabigatran%D0%94%D0%B0%D0%B1%D1%96%D0%B3%D0%B0%D1%82%D1%80%D0%B0%D0%BDDabigatranQ419345%E9%81%94%E6%AF%94%E5%8A%A0%E7%BE%A4
about
sameAs
P2176
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the BloodStudy to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)International Registry of Thrombotic APS Patients Treated With Direct Oral AnticoagulantsPredictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..
P4844
A specific antidote for dabigatran: functional and structural characterizationDabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.Determination of dabigatran in human plasma samples.Anticoagulation therapy. Dabigatran and risk of myocardial infarction.Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.Dabigatran: a primer for neurosurgeons.Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency.Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).An audience with... Gregory Lip. Interview by Asher Mullard.The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran.Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.Hemopericardium and cardiac tamponade associated with dabigatran use.An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial FibrillationCase of both rivaroxaban- and dabigatran-induced leukocytoclastic vasculitis, during management of pulmonary thromboembolismA hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinomaNew versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case ReportImmediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute StrokeOral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT studyEffectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation PatientsPhase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and designPharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic VariantsDabigatran causing severe acute kidney injury in a patient with liver cirrhosisDabigatran and atrial fibrillation: the alternative to warfarin for selected patientsPlasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy[Dabigatran and emergency operation on a peritonitis patient][The monitoring of application of dabigatran as a remedy of prevention of thromboembolic complications after hip joint arthroplasty]Dabigatran: rational dose individualisation and monitoring guidance is needed
P921
Q27684149-12D4E87F-33C7-4E63-9EAF-D5FACFE637CAQ35975334-FFF647C9-4ACF-4F45-B7EE-967C76639403Q37982268-33D47832-F76F-44FD-A83E-45D994251CC4Q37992920-2905EAA3-17CA-4D71-8666-AC583BB6D8CFQ37998109-2221DDB5-BE27-4E29-81BB-FB67EBB74E5BQ38020658-D03A891C-1DC2-4C43-83E0-CBA486A34BE4Q38469560-C256EDA6-CE26-428C-940E-CFAAB8CE7BD6Q42618094-79C2E784-1A88-4ABF-A271-7436CFFE5362Q43536725-FA3643B7-BC26-4F86-BBCA-83EA4F448B25Q45106075-0E2232D6-FDC0-4163-A0BC-3F4A4809C9EDQ47917364-9428BE86-19EB-4975-999A-FB240967B510Q48419814-f0f51165-43ea-ebf9-5a6f-1c206df9067fQ49073285-E5643A5D-646E-4DC0-A95D-CCB63FDDF4C5Q51175352-E544FF85-3D14-406E-B415-76E4818639F2Q51180285-6B659B92-3518-41DD-8532-E9D8EA3F81A3Q51325958-6A20FAC1-7FA8-46E1-A861-73DFF022EF42Q55056332-98EDA20C-2C59-49FD-BB94-E309D74EBE4EQ61807914-D7E45599-2B6D-4ECB-8BA4-A65D81873E22Q61809936-C13038E5-23D2-4459-B584-E53406DE8CB4Q64054594-05A5FB11-D09F-41B9-9173-8A6124F97382Q64083761-1E46015D-664C-4A25-ACEE-C3E9FB8D0499Q64086854-21B25A3E-525B-41E1-82BE-83ED36F69CB3Q64100006-0E59BF0B-3456-4BC2-A8A8-00C523CE5DC5Q64116367-C71439D1-E4EC-4C13-94FA-1ECB2DAD38F6Q64119437-4811D103-6C39-4B3E-A299-0008129ADB56Q64123340-D471C72C-0170-45B3-9BA5-C6E4551C3ED9Q64228972-C6678343-9BAB-4CA9-97FE-07E8B8BE92B6Q64299493-52F64171-5A5F-4576-BFBA-FA8D6FCA3FA0Q83633290-211778D9-1ED2-4086-A1F2-6D0701F65F98Q83698829-D917DCC7-8A65-45F3-926E-235B4655C61CQ84182067-DCE6D9C1-CED7-4307-9B3C-57772500AAA2Q84625671-421A84B5-E852-423B-9275-8D89F27625EFQ84703319-E5D5AE29-EFA1-497D-ACF8-19E94CE73789
P921
description
anticoagulant medication that can be taken by mouth
@en
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dabigatraani
@fi
Dabigatran
@da
Dabigatran
@de
Dabigatran
@fr
Dabigatran
@it
Dabigatran
@nl
Dabigatran
@sh
Dabigatran
@sr
Dabigatran
@vi
Dabigatrán
@es
type
label
Dabigatraani
@fi
Dabigatran
@da
Dabigatran
@de
Dabigatran
@fr
Dabigatran
@it
Dabigatran
@nl
Dabigatran
@sh
Dabigatran
@sr
Dabigatran
@vi
Dabigatrán
@es
altLabel
C34H41N7O5
@fr
Dabigatran
@es
Dabigatran
@pt
Dabigatran
@zh
Dabigatrana
@pt
Pradax
@zh
Pradaxa
@de
Pradaxa
@it
Pradaxa
@pl
Pradaxa
@zh
prefLabel
Dabigatraani
@fi
Dabigatran
@da
Dabigatran
@de
Dabigatran
@fr
Dabigatran
@it
Dabigatran
@nl
Dabigatran
@sh
Dabigatran
@sr
Dabigatran
@vi
Dabigatrán
@es
P638
P486
P592
P6366
P646
P661
P662
P665
P683
P1579
P2067
P2115
N0000181836